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Abstract
Background: It is important for public health and within the HIV vaccine development field to understand the potential
population level impact of an HIV vaccine of partial efficacy—both in preventing infection and in reducing viral load in
vaccinated individuals who become infected—in the context of a realistic future implementation scenario in resource
limited settings.
Methods: An individual level model of HIV transmission, progression and the effect of antiretroviral therapy was used to
predict the outcome to 2060 of introduction in 2025 of a partially effective vaccine with various combinations of efficacy
characteristics, in the context of continued ART roll-out in southern Africa.
Results: In the context of our base case epidemic (in 2015 HIV prevalence 28% and incidence 1.7 per 100 person years), a
vaccine with only 30% preventative efficacy could make a substantial difference in the rate with which HIV incidence
declines; the impact on incidence in relative terms is projected to increase over time, with a projected 67% lower HIV
incidence in 2060 compared with no vaccine introduction. The projected mean decline in the general adult population
death rate 2040–2060 is 11%. A vaccine with no prevention efficacy but which reduces viral load by 1 log is predicted to
result in a modest (14%) reduction in HIV incidence and an 8% reduction in death rate in the general adult population
(mean 2040–2060). These effects were broadly similar in multivariable uncertainty analysis.
Interpretation: Introduction of a partially effective preventive HIV vaccine would make a substantial long-term impact on
HIV epidemics in southern Africa, in addition to the effects of ART. Development of an HIV vaccine, even of relatively low
apparent efficacy at the individual level, remains a critical global public health goal.
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Introduction
There is evidence that incidence of HIV has declined in
countries in southern Africa, likely due to population level
awareness and changes in sexual risk behaviour, some effect of
antiretroviral therapy in reducing infectivity, and other factors
such as increased uptake of male circumcision [1]. However,
prevalence remains high [1]. While continued roll out of ART will
potentially lead to further reductions in incidence, and other
effective prevention measures such as pre-exposure prophylaxis
may be increasingly used, the need for additional approaches to
help to limit new infections remains. The need for an HIV vaccine
has been recognised from the start of the epidemic but progress
has been limited and substantial challenges remain [2]. It is
increasingly recognised that a vaccine with very high efficacy for
preventing infection may not be attainable for the foreseeable
future. Therefore it is relevant to consider what might be the
effects of a vaccine with efficacy of perhaps as low as 30%, the
estimated efficacy of the vaccine regimen used in the RV144 trial
[3], and/or a vaccine that has limited or no efficacy in reducing
risk of infection but which has efficacy in lowering viral load set
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point in people vaccinated (vaccinees) who become infected.
Quantifying the population-level impact of such vaccines, partic-
ularly those that reduce viral load set point in those infected, is far
from straightforward given the many inter-related factors that
need to be accounted for and their highly dynamic nature.
Mathematical models of HIV transmission are needed. In
particular, modelling HIV at the individual-level is important, to
account for the various heterogeneities between individuals and to
evaluate the impact of a prophylactic HIV vaccine that can have
effects on infection and on viral load in infected vaccinees. It is
likely to be additionally informative to assess this impact within a
realistic scenario which reflects current and potential future trends
in the high prevalence region of southern Africa. The results of
such modelling may guide vaccine development programmes,
bringing clarity on the relative importance of the two aspects of
efficacy and to understand the anticipated real life context into
which a vaccine would be introduced.
In this paper we use an individual-based model [4,5] to
investigate the population-level impact of vaccination with a
prophylactic HIV vaccine in a developing country setting with a
generalised heterosexual epidemic (as in southern Africa). The
model accounts for the natural history of the disease, the expanded
use of ART, including various heterogeneities between individuals,
in order to inform the public health community about the benefit
of a prophylactic HIV vaccine.
Methods
Mathematical model
The HIV Synthesis Heterosexual Transmission Model is an
individual-based stochastic model of heterosexual transmission,
progression and treatment of HIV infection, described briefly in
File S1, with full model details in previous supplementary
materials [4,5]. The basic model structure is shown in Figure 1.
All variables in the model are updated in 3 month periods. The
model includes an age-structure and the sexual risk behaviour is
modelled as the number of condomless-sex short term partners
and presence of a condomless-sex long-term partner in each
period.
For each short or long-term partner that a subject has in a 3
month period, the probability that the partner is infected is
calculated. For a short-term partner this depends on the age- and
sex- specific prevalence of HIV amongst those in short-term
partnerships. For a long-term partner, the HIV infection, diagnosis
and ART status is tracked over time; in any 3 month period an
uninfected long-term partner may become infected, dependent on
the age-specific HIV-incidence in the population, a new long-term
relationship with an infected short-term partner may form or a
relationship with an infected long-term partner may continue. For
exposure to each infected short- or long-term partner in the time
period, the probability of transmission depends on the viral load
level of the partner (for short-term partners this is obtained by
sampling from the distribution of viral load levels in partnerships
formed by HIV infected people, accounting for gender and age,
and for long-term partners this depends on diagnosis and use of
ART, estimated from the population of HIV-infected subjects), on
the estimated risk of transmission at that viral load, gender,
presence of a concurrent sexually transmitted infection in the
subject and for male subjects on whether or not they are
circumcised. If a subject is infected the probability of transmitted
drug resistance depends on the viral load of the partner who
infected the subject and viral load-specific population levels of
resistance. For HIV-infected subjects variables modelled include:
primary infection, CD4 count, viral load, presence of resistance,
HIV diagnosis, care and treatment and adherence to treatment.
Using a single set of parameter values, we generated an
epidemic from 1989–2025. Vaccine introduction scenarios are
considered from 2025 (when it is believed a vaccine could be
available, based on current status of the field and classical
development timelines). We keep the same set of parameter values
for the natural history of HIV, sexual risk behaviour and HIV
management and treatment but make multiple runs for each
Figure 1. Summary of key variables and main influences in
model. Effects of vaccine are illustrated in grey.
doi:10.1371/journal.pone.0107214.g001
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vaccine implementation scenario and take means, to minimize
stochastic effects on outcomes.
Epidemic/programmatic scenario modelled
Our model was not specifically calibrated to data from any one
country or region but broadly reflects historic levels of incidence
and prevalence in settings in southern Africa [6]. ART was
assumed introduced in 2003 with choice of drugs and monitoring
strategy over the period to the present consistent with WHO
guidelines of the time.
Vaccine scenarios
Prevention efficacy of 0%, 30%, 50% and 90% were
considered. Efficacy in reducing viral load set point at infection
in those infected (with consequent effects on CD4 count decline
and probability of viral suppression on ART as well as on
infectivity) was 0.0, 1.0 or 2.0 log10 copies/mL. We focused on
comparisons of outcomes of 8 different vaccine efficacy scenarios
defined according to the efficacy of the vaccine in preventing
infection and its efficacy in reducing viral load in infected
vaccinees as follows: (i) prevention efficacy 0%, viral load efficacy
0.0 log10, (ii) prevention efficacy 30%, viral load efficacy 0.0 log10,
(iii) prevention efficacy 50%, viral load efficacy 0.0 log10, (iv)
prevention efficacy 90%, viral load efficacy 0.0 log10, (v)
prevention efficacy 0%, viral load efficacy 1.0 log10, (vi) prevention
efficacy 0%, viral load efficacy 2.0 log10, (vii) prevention efficacy
50%, viral load efficacy 1.0 log10, (viii) prevention efficacy 90%,
viral load efficacy 2.0 log10. These 8 vaccine efficacy scenarios do
not represent all possible permutations of vaccine prevention and
viral load efficacy but were chosen a priori as a set of scenarios of
particular interest.
Duration of vaccine effect was assumed to be 2 or 5 years, with
the possibility of a tapered effect such that there is a linear decrease
in efficacy down to half the initial efficacy by the end of the
duration of the vaccine effect, i.e. efficacy was reduced by 50% by
the end of the 2 or 5 year period. While we primarily considered
that any vaccine effect would apply to all infected vaccinees, we
also considered the possibility that each of the effects would only
be present in half of those vaccinated. Considering uptake and
coverage, we assumed a three dose schedule with the first 2 doses
within the same 3 month period and the 3rd dose 6 months later.
Completion of the second dose, given the first was administered
was assumed to be 98% (assumed no efficacy if only first dose
administered), while completion of the dose after 6 months
amongst those with the first two doses was assumed to be 94%
(50% reduction in vaccination efficacy assumed if only first two
doses administered). Current vaccination programmes for HPV
vaccines will help to further inform these assumptions [7].
Vaccination at age 10 or age 15 were considered, with a rate of
vaccination per 3 months of 0.2 or 0.3 amongst those age 10–12 or
15–17 (depending on the target age for vaccination), with a
maximum coverage in this age group of either 40% or 70% (when
rate of uptake is 0.2 only 93% of this maximum coverage achieved
in 3 year vaccination period; 99% when rate is 0.3). We considered
the possibility that there might be a 5 year catch-up program in
adults aged 18–30 when the vaccine was first introduced, covering
50% of the population of that age. We also considered a scenario
in which the vaccine was only provided to those at higher risk –
defined as those having condom-less sex with a short-term in the
past year. We considered that there may be a booster every 2 years
or 5 years, depending on the duration of the assumed vaccine
effect, up to age 30 or age 50. We assumed that only either 25%,
50% or 80% of people who had the first three vaccine doses would
take these subsequent boosts (i.e. 75%, 50% or 20% of people
vaccinated would not have any subsequent boost). While we
generally assumed that those who took any booster would take all
of them we also considered a scenario in which completion rates
diminished over time such that only 80% of those who had a given
boost then had the next boost. We conservatively assumed that
vaccines that have an effect on viral load do not affect the
infectivity of the infected vaccinee during primary infection, due to
the fact that early high levels of viral replication are not greatly
affected by the HIV-specific immune response [8].
We initially considered main results for our base scenario
(vaccination at 15, with a rate of vaccination per 3 months of 0.3
amongst those age 15–17 (and a 5 year catch-up program amongst
adults age 18–30), with a maximum coverage (in 15–17 year olds)
of 70%, and with regular boosters every 5 years (the assumed
duration of vaccine effect) to age 50, with 80% of people
vaccinated then being adherent to all these subsequent boosts). In
sensitivity analyses, we explored the effect of varying the vaccine or
implementation characteristics in various ways, leaving all other
parameters fixed.
Multivariable uncertainty analysis
We also conducted a multivariable uncertainty analysis in which
we simultaneously and independently sampled underlying model
parameter values (for the natural history of HIV, sexual risk
behaviour, HIV diagnosis, management and treatment) as
specified in File S1, and generated the HIV epidemic from
1989–2025. For each of 500 model runs, from 2025–2060 we kept
the sampled model parameter values fixed and generated the HIV
epidemic for each of the 8 vaccine scenarios.
Results
We first describe the characteristics of the modelled population
in 2025, the year which we assumed a vaccine to be introduced
(Table 1). The HIV prevalence is 25%, where 77% of people
living with HIV are diagnosed, 71% of those diagnosed are under
care, and 61% of the entire HIV infected population is on ART.
This is not intended to correspond to one specific population in
southern Africa but the profile is broadly in line with epidemic and
programme data from the region.
We then considered projected outcomes from 2025–2060
according to vaccine efficacy characteristics. These are shown in
Figure 2 and Figure S1 in File S1, in the context of the base
scenario for vaccination. Differences in outcomes (HIV incidence,
prevalence, percent of the whole population on ART, death rate in
the whole population, and the percent of people with on-going
vaccine effect) generally emerge gradually as vaccine coverage
increases so in Table 2 we focus on differences from 2040 onwards
by giving the mean of values of the outcomes over the period from
2040–2060. The proportion of the adult population vaccinated
and with some on-going vaccine effect (i.e. vaccinated previously
and still within the period of vaccine efficacy) rises to over 20% by
2028, within 2–3 years of the program initiation, and thereafter
increases gradually to a ceiling level of around 45% over 25 years
(by 2050; see Figure S1q, S1r in File S1).
Impact on incidence and prevalence
Next we considered the impact of the potential vaccine on
incidence and prevalence of HIV infection in the population.
While due to a combination of ART, increased circumcision and
previous changes in condomless sex a decline in HIV incidence is
predicted to occur (Figure 2a) even without any vaccine introduc-
tion (prevention efficacy and viral load efficacy both 0, see line in
blue in Figure 2a), the predicted decline is markedly greater if a
Impact of a Partially Effective HIV Vaccine
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vaccine with prevention efficacy is introduced. Notably, even for a
vaccine with 30% prevention efficacy (and no effect on viral load)
there is a substantial effect, with a 52% reduction in mean HIV
incidence 2040–2060 (3.7 per 1000 person years compared with
7.7 per 1000 person years with no vaccine) and a projected 67%
lower HIV incidence in 2060 compared with no vaccine
introduction. Vaccines with 50% and 90% efficacy lead to
predicted mean incidence in 2040–2060 of 2.3 and 1.0 per 1000
person years, respectively. There is also an effect of a vaccine with
viral load efficacy but no direct prevention efficacy on mean HIV
incidence in 2040–2060 (6.6 and 5.2 per 1000 person years for a
vaccine that reduces viral load set point by 1.0 log and 2 log,
respectively). Differences in trends in HIV prevalence (Figure 2b)
according to vaccine efficacy characteristics tend to follow the
differences in HIV incidence.
Impact on death rate, ART use and other key outputs
We then considered predicted differences in death rate
according to the vaccine introduction scenarios. The death rate
for people with HIV (Figure 2c) is highest in the scenario with
highest vaccine prevention efficacy considered (90%), and lowest
where there is no prevention efficacy and the highest viral load
efficacy considered (2.0 log reduction). This is due to the selection
effects on the HIV infected population; because there are less new
HIV infections the population living with HIV is composed mainly
of people who have been infected for a longer while and so are
more likely to die. Figure 2d shows the death rate in the whole
population, including infected and uninfected, which captures
benefits of both prevention efficacy and viral load efficacy. Both
forms of efficacy have a distinct beneficial effect on mortality in the
population, although with a prevention efficacy of 90% there is
little additional impact of a 2 log viral load efficacy.
Another issue to consider, are predicted changes in the use of
ART. There are accompanying large reductions in the proportion
of the whole adult population on ART (Figure 2e) which broadly
follow the trends in HIV prevalence. Figure 2f shows the
proportion of the whole adult population with viral load .1000
copies/mL, indicating the effects of the two types of vaccine
efficacy on the number of infectious people in the population. HIV
incidence is driven by this population of infectious people, and the
curves follow a similar pattern to those for HIV incidence.
Predicted trends in the proportion of HIV positive people with
CD4 count 350 are shown in Figure 2g. This proportion is highest
where no vaccine is introduced and lowest where a vaccine with
viral load efficacy, but no prophylactic efficacy, is introduced. The
proportion of people with HIV who are diagnosed (Figure 2h) is
predicted to be highest for a vaccine with high prophylactic
efficacy. Both of these trends relate to the overall changing
breakdown of the future HIV positive population resulting from
selection effects due to fewer new infections (particularly with
Table 1. Characteristics of the population up to and at baseline (year 2025).*
HIV prevalence 1989 2%
1990 7%
1995 21%
2000 25%
2005 26%
2010 28%
2015 28%
2020 27%
2025 25%
Incidence of HIV (/100 person years) 1990 6.6
1995 4.5
2000 2.7
2005 2.2
2010 2.3
2015 1.7
2020 1.6
2025 1.3
Death rate 2020–2025 (/100 person years) Whole population 1.50
HIV infected population 4.23
Percentage of people with HIV diagnosed 77%
Percentage of people with HIV diagnosed and under care 71%
Percentage on ART Of whole population 15%
Of HIV infected 61%
Of HIV diagnosed 79%
Percentage with viral load ,500 copies/mL Of HIV infected 50%
Of people on ART 79%
Percentage of all HIV infected with any drug resistance mutation 17%
*all values relate to 2025 unless stated.
doi:10.1371/journal.pone.0107214.t001
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vaccines with prophylactic efficacy) and/or lower viral load in
those becoming infected (for vaccines with viral load efficacy). The
degree of ongoing prophylactic vaccine efficacy is shown in
Figure 2i.
Analysis of sensitivity to assumptions on vaccine
characteristics
We then explored the extent to which our main findings
described above differed when various changes in the vaccine-
related parameters and assumptions were made. Table 3 (with full
details in Table S1 in File S1) shows the effect of several variations
in the vaccine-related parameters and assumptions, with one factor
varied at a time. The average proportion of people aged 15–65
with on-going vaccine efficacy in the years 2040–2060 is at its
highest at 45% (the coverage values of 40% and 70% relate to the
proportion of people in the target age range (10–12 or 15–17) who
are vaccinated - aside from the initial adult catch-up program,
those who are not vaccinated by age 18 are assumed not
vaccinated at all in their lifetime). The different variations in effect
all led to various degrees of reduced on-going vaccine impact and
this was generally correlated as expected with the effect on
incidence and the death rate in the whole population. The average
percent with on-going vaccine effect was lowest across all scenarios
with only 25% booster completion rate. For some variations, the
modification of the effect on incidence was only small, such as
when the rate of vaccination was decreased from 0.3 to 0.2 per 3
months, or when the duration of vaccine efficacy was reduced
from 5 to 2 years. The reason for the small impact of the latter
variation is that it is assumed that booster doses are given after 2
rather than 5 years, so there is little detrimental effect on vaccine
coverage (44% vs 45% in the base scenario). Vaccination at age
15, rather than age 10, is associated with greater vaccine effects,
presumably due to the fact that people vaccinated at age 15 have
immediate benefits (because they are already potentially sexually
active) while, with vaccination at age 10, efficacy may be lost
before sexual activity commences.
Multivariable uncertainty analysis
For all the results shown above be made a set of assumptions
and used certain parameter values for our underlying model
(described in Figure 1). We therefore explored what variation
there is in our main results if these assumptions are varied. In this
mutivariable uncertainty analysis we varied all the parameters as
described by the distributions in File S1. For each simulation run
we independently sampled from each of the distributions as
described. This is in contrast to the one way sensitivity analysis
above that focussed only on varying the vaccine-related charac-
teristics, and also only one assumption was varied at a time. In this
analysis we focussed on our main comparison of incidence rates
between the vaccines with various characteristics, and present
these in the form of incidence rate ratios. Table 4 shows the
distribution of incidence rate ratios, compared with the no vaccine
scenario, for the 8 vaccine efficacy scenarios. Generally, the effects
were of similar magnitude across the 500 runs but there was some
appreciable variation. For example, the median incidence rate
ratio over 2040–2060 for a vaccine of 30% prevention efficacy
(0.48 in our base case analysis) was 0.59 with a 90% uncertainty
range of 0.41–0.79. Overall, our choice of parameter distributions
used in these analyses were such that the vaccine effects we saw in
our base case scenario were slightly greater than the median effect
in the uncertainty analysis.
Discussion
These results from a detailed individual-based simulation model
of the potential effects of a partially effective HIV vaccine on
epidemics in southern Africa, in the context of assumed continued
expansion of ART use, suggests that even a vaccine with 30%
preventative efficacy could make a substantial difference in the
rate with which HIV incidence declines. The impact on incidence
in relative terms is projected to increase over time, with a projected
67% lower HIV incidence in 2060 compared with no vaccine
introduction, which reflects the additional population impact due
to effects of herd immunity. A vaccine with 50% prevention
efficacy (but no effect on viral load) is predicted to reduce
incidence in our scenario to around 0.11% per year in 2060,
compared with 0.64% per year without a vaccine being
introduced. A vaccine with no prevention efficacy but which
reduces viral load by 1 log is predicted to result in some modest
(14%) reduction in mean HIV incidence in 2040–2060 and to lead
to an 8% decrease in death rate in the whole adult population
(mean 2040–2060), while if viral load is reduced by 2 log then
these reductions are 32% and 13%, respectively (Table 2). These
results all relate to our base case scenario (illustrated by the results
presented in Table 1) which we considered to be realistic.
However, results on the effect of vaccines on HIV incidence were
robust in multivariable uncertainty analyses in which we
considered a wide range of epidemic/programmatic situations
by simultaneously sampling multiple parameters from distributions
reflecting uncertainty in their value. Our model can be used in the
future to predict vaccine effects in any specified implementation
scenario.
While prediction of the absolute future incidence of HIV in the
absence of a vaccine is not the primary focus on this work, it is
notable that our modelling predicts a continued decline in HIV
incidence over the coming years in the absence of any vaccine
introduction, consistent with other modelling estimates [1]. We
assume continuation of ART roll-out had some effect on the
resulting incidence over time (Figure S1g in File S1). While we do
not assume further general population reductions in condom-less
sex in this period, the effects of the earlier reductions may still be
playing out in the period under study. Also, we do continue to
assume a reduction in condom-less sex as a result of HIV diagnosis
(average 17% reduction with new partners and 31% reduction
with primary partners; for this reason we did not explicitly
incorporate the fact that people would likely need to be tested HIV
negative before being vaccinated, because the resulting higher
levels of HIV testing and diagnosis would add an indirect benefit
of vaccination which is difficult to separate from the intrinsic
effect). These are likely to be the main reasons behind the
continued predicted decline in incidence. If the ART roll out stalls
Figure 2. Predicted outcomes 2025–2060 of eight vaccine introduction scenarios in 2025. (i) prevention efficacy 0.0, viral load efficacy 0.0
log10, (ii) prevention efficacy 30%, viral load efficacy 0.0 log10, (iii) prevention efficacy 50%, viral load efficacy 0.0 log10, (iv) prevention efficacy 90%,
viral load efficacy 0.0 log10, (v) prevention efficacy 0.0, viral load efficacy 1.0 log10, (vi) prevention efficacy 0.0, viral load efficacy 2.0 log10, (vii)
prevention efficacy 50%, viral load efficacy 1.0 log10, (viii) prevention efficacy 90%, viral load efficacy 2.0 log10. All in the context of vaccination at 15,
with a rate of vaccination per 3 months of 0.3 amongst those age 15–17 (and a 5 year catch-up program amongst adults age 18–30 covering 50% of
the population of that age), with a maximum coverage (in 15–17 year olds) of 70%, and with regular boosters every 5 years (the assumed duration of
vaccine effect) with 80% of people being adherent to these boosts.
doi:10.1371/journal.pone.0107214.g002
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then this would adversely affect future HIV incidence, as would
any general population increases in condom-less sex. Such
increases could occur as fear of HIV declines due to availability
of ART or if focus and spending on prevention is diminished in the
interests of expanded ART. Likewise there could be a specific
tendency for people who are vaccinated to increase condom-less
sex due to a feeling of protection from infection, which could make
a major impact on net vaccine efficacy and could even potentially
lead to an increase in incidence. Such ‘‘risk compensation’’ is a
general concern for new prevention interventions and will be
critical to study along with any vaccine trial and roll-out [9,10].
We assume no substantial increase in male circumcision, with
around 20% of men circumcised, or any use of antiretroviral-
based pre-exposure prophylaxis, due to uncertainty over the extent
of its future use. Another factor that could influence future
incidence is the potential tendency for increased viral pathoge-
nicity over time (which has been observed in some cohorts [11]),
leading to continuation of the observed trend for lower initial CD4
count, causing earlier ART initiation and death in those not
diagnosed, leading to greater reductions in incidence. Lastly, our
model takes account of the development of drug resistance and its
transmission, so the predicted improvements occur despite some
increase in drug resistance [5,12].
Various HIV transmission models, including some individual-
based simulations models [13–15] have been used to analyse
potential effects of HIV vaccines [13–32]. These have yielded
insights consistent with some of our own observations. The finding
that partially effective prophylactic vaccines, if effectively boosted
so that vaccine efficacy levels are kept close to the maximal (albeit
modest) effect, can have a substantial impact on reducing HIV
incidence has been observed since early studies [18,21,23]. The
potential effects of the ALVAC-HIV prime, AIDSVAX B/E
antigen boost vaccine regimen in a trial in Thailand (with
estimated 30% efficacy; RV144 trial [3] have been extensively
modelled in various settings. While one round of vaccination was
not predicted to have large effects, when on-going boosting at
intervals was considered, predicted effects were substantial and the
vaccine cost-effective [15,29,31,32]. Some models have also taken
account of the potential effect of a vaccine in reducing viral load,
and hence infectivity and rate of CD4 count decline
[17,19,20,25,33], but no individual-based stochastic models to
our knowledge has previously taken account of all these factors in
the context of detailed modelling of effects of ART. The one
vaccine showed to have (partial) success in reducing HIV
incidence, in the RV144 trial, did not appear to have any effect
on viral load in infected vaccinees [3].
We have highlighted the strength of this modelling analysis but
there are also limitations. By the nature of a modelling analysis, we
made a number of assumptions, some of which are particularly
uncertain considering that we project over almost a 50 year
period. However, we did assess the variation in our key findings
according to variations in these assumptions and found the basic
results and conclusions to be stable. Our assumption of the level of
vaccine uptake may seem relatively optimistic for a vaccine to be
provided to adolescents but in context of high awareness of HIV
and current levels of ART access we feel they are probably realistic
considering that several countries in Africa have over 60%
coverage of ART. Nonetheless, we also found a substantial effect if
vaccine coverage was 40% rather than 70%.
In conclusion, introduction of a partially effective HIV vaccine
would be predicted to make a substantial long term impact on
HIV epidemics in southern Africa. Development of an HIV
vaccine, even of relatively low efficacy, remains a critical public
health goal.
Supporting Information
File S1 Supplementary Methods and Results. (i) Brief descrip-
tion of HIV Synthesis Heterosexual Transmission Model for
southern Africa, (ii) Epidemic scenario modelled, (iii) Vaccine and
implementation characteristics, (iv) Full model details, (v) Param-
eters and distributions for uncertainty analysis, (vi) Table S1
(Mean over 2040–2060 of the following outcomes: HIV incidence
(per 1000 person years), prevalence (%), % of whole population on
ART (not only HIV infected), death rate (in whole population; per
100 person years), % of uninfected population age 15–65 with an
on-going vaccine effect (i.e. vaccinated and up to date with
boosters), 2040–2060, according to vaccination efficacy and
implementation characteristics. 95% CI shown in grey), (vii) Figure
S1 (Predicted outcomes 2025–2060 of eight vaccine introduction
scenarios in 2025: (i) prevention efficacy 0.0, viral load efficacy
0.0 log10, (ii) prevention efficacy 0.3, viral load efficacy 0.0 log10,
(iii) prevention efficacy 0.5, viral load efficacy 0.0 log10, (iv)
prevention efficacy 0.9, viral load efficacy 0.0 log10, (v) prevention
efficacy 0.0, viral load efficacy 1.0 log10, (vi) prevention efficacy
0.0, viral load efficacy 2.0 log10, (vii) prevention efficacy 0.5, viral
load efficacy 1.0 log10, (viii) prevention efficacy 0.9, viral load
efficacy 2.0 log10. All in the context of vaccination at 15, with a
rate of vaccination per 3 months of 0.3 amongst those age 15–17
(and a 5 year catch-up program amongst adults age 18–30
Table 4. Multivariable uncertainty analysis based on 500 runs.
Prevention efficacy Viral load efficacy (log10)
Incidence rate ratio (vs. no vaccine) 2040–60
Median (90% uncertainty range) over runs in which parameters vary Base case
30% 0.0 0.59 (0.41–0.79) 0.48
50% 0.0 0.39 (0.21–0.60) 0.30
90% 0.0 0.17 (0.10–0.37) 0.13
0% 1.0 0.87 (0.69–1.09) 0.86
0% 2.0 0.77 (0.56–1.05) 0.68
50% 1.0 0.38 (0.23–0.58) 0.30
90% 2.0 0.16 (0.09–0.40) 0.13
Variation in effect of vaccine on HIV incidence under parameter variation, sampling from distributions of parameter values given in Supplementary Methods and Results
in File S1.
doi:10.1371/journal.pone.0107214.t004
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covering 50% of the population of that age), with a maximum
coverage (in 15–17 year olds) of 0.7, and with regular boosters
every 5 years (the assumed duration of vaccine effect) with 80% of
people being adherent to these boosts. See footnote for full
description of variable definition).
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